Recombinant adenoviruses have been one of the intensively investigated viral vectors for therapeutic purposes. Development of the novel methods for manipulating of the viral genome resulted in the three generations of the recombinant adenoviruses and with increasing capacity [125] (Figure 2 ). Several trials imply the usefulness of those vectors in gene therapy of genetic diseases and cancer [134] [135] [136] [137] . For many years, the first generation replication-deficient E1 or E1/E3-deleted adenoviral vectors have been explored as the vaccine carriers in prevention of the infectious diseases [138] . Adenoviral vectors have several advantages that can be beneficial for potent therapeutic vaccines.